DUBLIN, July 26, 2023 /PRNewswire/ -- The "Anti-Neutrophil Cytoplasmic Antibody - Associated Vasculitis - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to
ResearchAndMarkets.com's offering.
Patients suffering from ANCA Associated Vasculitis often have general symptoms initially, and the disease requires multiple specialties like rheumatologists, pulmonologists, and nephrologists to diagnose. Due to advancements in healthcare infrastructure and new diagnostic techniques, the tendency toward diagnosis is rising in the United States. In 2022, the market size of ANCA Associated Vasculitis was highest in the US among the 7MM (United States, EU4, and Japan), accounting for approximately USD 620 million. This market size is expected to increase by 2032. FASENRA (benralizumab) by AstraZeneca: FASENRA is a monoclonal antibody that depletes blood and tissue eosinophils by binding to the IL-5 receptor. It is being evaluated in clinical trials for the treatment of EGPA and is expected to compete with NUCALA in the EGPA patient segment. The total diagnosed prevalent cases of ANCA-associated vasculitis in the 7MM were approximately 207,900 cases in 2022. The United States had the highest number of cases, accounting for around 70,700 cases. Among the EU4 countries, Germany had the highest number of cases, followed by the UK. Japan had diagnosed prevalent cases of MPA, GPA, and EGPA in 2022, and these cases are projected to increase during the forecast period. The ANCA Associated Vasculitis market is expected to grow substantially in the coming years. The market size in the 7MM is projected to increase at a compound annual growth rate of 6.9%. The emerging therapies, including TAVNEOS, NUCALA, and other potential treatments, are expected to drive market growth. Vilobelimab and depemokimab are projected to generate the highest revenue among the emerging therapies. The ANCA Associated Vasculitis market is experiencing growth due to increased awareness and advancements in healthcare infrastructure. TAVNEOS and NUCALA are approved treatments for different subtypes of ANCA-associated vasculitis, and emerging therapies like benralizumab, depemokimab, and vilobelimab show promise in improving treatment options. The market size is expected to expand, and there is a need for innovative treatments to address the unmet needs of patients. Access and reimbursement policies, as well as the availability of generics, will also impact the market dynamics. 5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Epidemiology and Patient Population
13. Market Access and Reimbursement
A selection of companies mentioned in this report includes:
For more information about this report visit https://www.researchandmarkets.com/r/ffsul6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets